Intra- and interindividual attack frequency variability of chronic cluster headache

• Published in: Cephalalgia Vol. 43; no. 2; p. 3331024221139239
• Main Authors: Brandt, Roemer B, Mulleners, Wim, Wilbrink, Leopoldine A, Brandt, Paul, van Zwet, Erik W, Huygen, Frank JPM, Ferrari, Michel D, Fronczek, Rolf
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.02.2023
• Subjects: Cluster Headache - diagnosis; Cluster Headache - therapy; Humans; Retrospective Studies; Treatment Outcome; Cluster headache; clinical trials; headache
• ISSN: 0333-1024; 1468-2982
• DOI: 10.1177/03331024221139239

Background The lack of knowledge about the intra- and interindividual attack frequency variability in chronic cluster headache complicates power and sample size calculations for baseline periods of trials, and consensus on their most optimal duration. Methods We analyzed the 12-week baseline of the ICON trial (occipital nerve stimulation in medically intractable chronic cluster headache) for: (i) weekly vs. instantaneous recording of attack frequency; (ii) intra-individual and seasonal variability of attack frequency; and (iii) the smallest number of weeks to obtain a reliable estimate of baseline attack frequency. Results Weekly median (14.4 [8.2–24.0]) and instantaneous (14.2 [8.0–24.5]) attack frequency recordings were similar (p = 0.20; Bland-Altman plot). Median weekly attack frequency was 15.3 (range 4.2–140) and highest during spring (p = 0.001) compared to the other seasons. Relative attack frequency variability decreased with increasing attack frequency (p = 0.010). We tabulated the weekly attack frequency estimation accuracies compared to, and the associated deviations from, the 12-week gold standard for different lengths of the observation period. Conclusion Weekly retrospective attack frequency recording is as good as instantaneous recording and more convenient. Attack frequency is highest in spring. Participants with ≥3 daily attacks show less attack frequency variability than those with <3 daily attacks. An optimal balance between 90% accuracy and feasibility is achieved at a baseline period of seven weeks. The ICON trial is registered in ClinicalTrials.gov under number NCT01151631.